SCHEMBL3496985

SCHEMBL3496985

FC1(F)CC[C@@H](c2ccc(Br)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
LIG1 P18858 1/20 0.39
S1PR4 O95977 5/20 0.38
S1PR1 P21453 5/20 0.38
S1PR3 Q99500 5/20 0.38
S1PR5 Q9H228 5/20 0.38
ESR2 Q92731 3/20 0.36
ESR1 P03372 1/20 0.36
KDM1A O60341 7/20 0.35
RCOR1 Q9UKL0 4/20 0.35
KCNH2 Q12809 2/20 0.35
MAOB P27338 2/20 0.35
KDM1B Q8NB78 1/20 0.35
BRD4 O60885 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5426053 1.00 TSHR (0.43) TSHRLIG1S1PR4S1PR1S1PR3
SCHEMBL3496987 1.00 TSHR (0.43) TSHRLIG1S1PR4S1PR1S1PR3
SCHEMBL26086875 0.88 TSHR (0.42) TSHRLIG1S1PR4S1PR1S1PR3
SCHEMBL10216 0.84 KDM1A (0.40) TSHRLIG1KDM1ARCOR1KCNH2
SCHEMBL23319996 0.81 ESR2 (0.56) ESR2ESR1
SCHEMBL13499936 0.81 MAOB (0.41) S1PR4S1PR1S1PR3S1PR5ESR2
SCHEMBL13499921 0.81 MAOB (0.41) S1PR4S1PR1S1PR3S1PR5ESR2
SCHEMBL13499042 0.78 MGLL (0.40) S1PR4S1PR1S1PR3S1PR5ESR2
SCHEMBL14580445 0.78 MGLL (0.40) S1PR4S1PR1S1PR3S1PR5ESR2
SCHEMBL13499054 0.78 MGLL (0.40) S1PR4S1PR1S1PR3S1PR5ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659294-B2 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists MERCK & CO., INC. (US) 2010-02-09 US disclosed
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists MERCK SHARP & DOHME CORP. 2009-02-12 US disclosed
CN-101043887-A 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists MERCK & CO INC (US) 2007-09-26 CN disclosed
EP-1804793-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS Merck & Co., Inc. (US) 2007-07-11 EP disclosed
WO-2006047195-A2 2-(ARYL)AZACYCLYLMETHYL CARBOXYLATES, SULFONATES, PHOSPHONATES, PHOSPHINATES AND HETEROCYCLES AS S1P RECEPTOR AGONISTS MERCK & CO., INC. (US) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042954-A1 2-(Aryl)Azacyclylmethyl Carboxylates, Sulfonates, Phosphonates, Phosphinates and Heterocycles as S1p Receptor Antagonists S1PR1, S1PR3, S1PR5 TSHR 1055/4885LIG1 1380/4885S1PR4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.